Marissa Fox

Policies allowing teens to consent to human papillomavirus (HPV) vaccination may be a key strategy in improving vaccine uptake in adolescent populations, according to a research report published in 

The HPV vaccine is important in preventing disease and has proven safety and efficacy. Despite this, data reveal only 54% of adolescents in the United States are vaccinated with the complete HPV vaccine series.

Researchers evaluated the link between consent for the HPV vaccine and vaccination rate. Using data from a national dataset, investigators broke adolescents up into 2 categories based on whether they were or were not able to consent to vaccination.

The study cohort included data from 81,899 teenagers, collected between 2015 and 2018 from the states that allow adolescent consent to vaccination, including Alabama, Alaska, California, Delaware, Idaho, New York, Oregon, and South Carolina, as well as Washington, DC. Participants were aged 13 to 17 years (mean age, 15±1.4 years) and 49% were girls.

Those who received the first dose of the series of HPV vaccine doses was in states that allowed adolescent consent, 67.9% of adolescents began the HPV vaccine series, vs 61.4% among adolescents who were not able to consent due to state laws. Completion of all 3 HPV vaccination doses was 53.7% among adolescents, compared with 47.9% who could not consent.

In the sensitivity analysis, vaccine series initiation was significantly associated with the ability to consent. According to researchers, this analysis “revealed a significant positive association between adolescent being permitted to consent to HPV vaccination by state laws in their location of residence and increased rates of initiation of the vaccine series.”

Study limitations include the “cross-sectional nature” of the analyses, which prevented the researchers from establishing causality.

“This suggests that policies that permit adolescents to consent to HPV vaccination could be an important strategy toward improving vaccine initiation among young adolescents, when the vaccine is most likely to be effective,” the researchers concluded.

1. Ashlynn R. Torres BA. State Laws Permitting Adolescent Consent to Human Papillomavirus Vaccination and Rates of Immunization. 

Articles

State legislation that allows adolescents to choose to receive the HPV vaccine without parental interference would elevate immunization rates, according to a new study.

HPV vaccine rates rise in teens when they can consent, research shows

Study findings published in The BMJ reveal that the use of menopausal hormone therapy (MHT) is not strongly linked to an increased risk of developing dementia in women.

MHT is a therapy used to relieve menopausal symptoms in women. These symptoms include hot flashes, trouble sleeping, mood swings, depression, and even memory loss. Treatments include tablets containing oestrogen only, or a combination of oestrogen and progestogen. Additionally, there are treatments in the form of patches, gels and creams.

Studies and small trials have suggested a beneficial link between oestrogen and age-related brain decline. However, the largest trial of MHT, the Women’s Health Initiative Memory Study, found an increased risk of developing dementia among users of oestrogen-progestogen treatments.

A large observational study conducted in Finland showed an increased possibility of developing Alzheimer’s disease in users of both oestrogen-only and oestrogen-progestogen treatments. There were some methodological weaknesses in the study, however. To address this, researchers at the Universities of Nottingham, Oxford and Southampton investigated the risks of developing dementia using any of the menopausal hormone therapy treatments commonly prescribed within the UK National Health Service.

Scientists used two United Kingdom primary care databases, QResearch and Clinical Practice Research Datalink, to analyze MHT prescriptions for the 118,501 women aged 55 and older diagnosed with dementia between 1998 and 2020.

All information from MHT prescriptions given more than three years before the case diagnosis was evaluated, including hormone type, dose, and method of administration. Other factors, such as family history, smoking, alcohol consumption, pre-existing conditions, and other medications taken were considered. 16,291 cases and 68,726 controls had been exposed to menopausal hormone therapy in the period up to three years before diagnosis.

However, an analysis of cases with a specific diagnosis of Alzheimer’s disease showed a small increase in risk associated with oestrogen-progestogen therapy. This increased slowly with each year of exposure, reaching an average 11 percent increased risk for use of between 5 and 9 years. There was an average of 19 percent for use of 10 years or more.

This is an observational study, so cause cannot be established, and the researchers acknowledge limitations, such as incomplete recording of menopausal symptoms, particularly for women registered after menopause, that may have affected results.

“The findings will be helpful to policy makers, doctors, and patients when making choices about hormone therapy,” they conclude.1

1. Use of Menopausal hormone therapy and risk of dementia: Nested case-control studies using QResearch and CPRD databases. The BMJ. Accessed October 5, 2021 doi: 

This article was originally posted on Drug Topics®. 

A study published in The BMJ reveals that menopausal hormone therapy is not linked to an increased risk of developing dementia in women.

No link between dementia and menopausal hormone therapy

 Association revealed that there has been a 25% increase of cannabis use in early pregnancy since March of 2020. The study was conducted by Kaiser Permanente and evaluated 100,000 pregnancies in Northern California from 2019 to 2020.

Prior to the pandemic, the study reveals that approximately 6.75% of pregnant women were cannabis users and this has risen to over 8.14% during the pandemic. Kelly Young-Wolff, PhD, MPH describes this increase possibly linked to increased trauma, anxiety, and depression during the pandemic.

The study looked at urine toxicology tests for cannabis from the first prenatal visit for 100,005 pregnancies from January 2019 to December 2020 for data. This trend draws concern due to the reported potential risks to babies such as birth weight being affected and possible neurodevelopmental issues.

Deborah Ansley, MD, regional medical director for Kaiser Permanente’s Early Start prenatal health programexplains, “We need to get the word out more effectively that cannabis is not a healthy choice during pregnancy.”

1. Cannabis use by pregnant women increased during pandemic. News Release. EurekAlert! https://www.eurekalert.org/news-releases/929586. Accessed September 27, 2021.

A study released in JAMA reveals a 25% increase in cannabis use in pregnant women during the pandemic in the United States.

Marissa Fox

Articles

HPV vaccine rates rise in teens when they can consent, research shows

No link between dementia and menopausal hormone therapy

More pregnant women using cannabis amid pandemic